ATE455127T1 - Humane anti-humane cd3-bindungsmoleküle - Google Patents

Humane anti-humane cd3-bindungsmoleküle

Info

Publication number
ATE455127T1
ATE455127T1 AT04739377T AT04739377T ATE455127T1 AT E455127 T1 ATE455127 T1 AT E455127T1 AT 04739377 T AT04739377 T AT 04739377T AT 04739377 T AT04739377 T AT 04739377T AT E455127 T1 ATE455127 T1 AT E455127T1
Authority
AT
Austria
Prior art keywords
human
binding molecules
complex
provides
binding
Prior art date
Application number
AT04739377T
Other languages
English (en)
Inventor
Peter Kufer
Tobias Raum
Meera Berry
Roman Kischel
Susanne Mangold
Eva Krinner
Birgit Kohleisen
Steven Zeman
Christian Itin
Patrick Baeuerle
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Application granted granted Critical
Publication of ATE455127T1 publication Critical patent/ATE455127T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Liquid Crystal Substances (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04739377T 2003-05-31 2004-05-26 Humane anti-humane cd3-bindungsmoleküle ATE455127T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03012132 2003-05-31
PCT/EP2004/005684 WO2004106380A2 (en) 2003-05-31 2004-05-26 Human-anti-human cd3 binding molecules

Publications (1)

Publication Number Publication Date
ATE455127T1 true ATE455127T1 (de) 2010-01-15

Family

ID=33483897

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04739377T ATE455127T1 (de) 2003-05-31 2004-05-26 Humane anti-humane cd3-bindungsmoleküle

Country Status (9)

Country Link
US (1) US8784821B1 (de)
EP (1) EP1629011B1 (de)
AT (1) ATE455127T1 (de)
AU (1) AU2004242845B2 (de)
CA (1) CA2523716C (de)
DE (1) DE602004025101D1 (de)
DK (1) DK1629011T3 (de)
SI (1) SI1629011T1 (de)
WO (1) WO2004106380A2 (de)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
AU2003256299A1 (en) 2002-07-01 2004-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
MXPA06014075A (es) 2004-06-03 2007-03-15 Novimmune Sa Anticuerpos anti-cd3 y metodos de uso de los mismos.
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
CA2604032C (en) * 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
ES2417065T3 (es) 2005-04-26 2013-08-05 Trion Pharma Gmbh Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer
EP2004695A2 (de) 2005-07-08 2008-12-24 Xencor, Inc. Optimierte anti-ep-cam-antikörper
AU2011265342B2 (en) * 2005-07-18 2014-12-04 Amgen Inc. Human anti-B7RP1 neutralizing antibodies
DK1915398T3 (en) 2005-07-18 2016-07-04 Amgen Inc Humane anti-B7RP1 neutraliserende antistoffer
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
JP5686953B2 (ja) * 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
JP2009521474A (ja) * 2005-12-21 2009-06-04 メディミューン，エルエルシー ＥｐｈＡ２ＢｉＴＥ分子およびその使用
EP1996716B1 (de) 2006-03-20 2011-05-11 The Regents of the University of California Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
US8663635B2 (en) 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
CA2673725C (en) * 2006-12-20 2016-01-12 Mmr Information Systems, Inc. Antibodies and methods for making and using them
AU2013202392B2 (en) * 2006-12-20 2016-02-25 Mmrglobal, Inc. Antibodies and methods for making and using them
SG10201808730VA (en) 2007-04-03 2018-11-29 Amgen Res Munich Gmbh Cross-species-specific binding domain
CN109456410B (zh) 2007-04-03 2022-01-28 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
SI2199390T1 (sl) 2007-08-30 2017-02-28 Daiichi Sankyo Company, Limited Proti-epha2 protitelo
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
KR20100132998A (ko) 2008-04-04 2010-12-20 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 종양 성장, 혈관신생 및 전이를 차단하는 것을 목표로 하는 암에 대한 항체
CA2738568C (en) 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
SG194399A1 (en) 2008-10-01 2013-11-29 Amgen Res Munich Gmbh Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
EP4180458A1 (de) 2008-10-01 2023-05-17 Amgen Research (Munich) GmbH Bispezifischer einkettiger psma x cd3-antikörper mit artenübergreifender spezifität
DK2352763T4 (da) 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
US8703920B2 (en) * 2008-11-10 2014-04-22 The Regents Of The University Of California Fully human antibodies against N-cadherin
EP3495000A1 (de) 2009-02-17 2019-06-12 Cornell Research Foundation, Inc. Verfahren und kits zur diagnose von krebs und vorhersage des therapeutischen werts
MX337600B (es) 2009-12-02 2016-03-11 Imaginab Inc Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antigeno de membrana especifico para prostata de humano (psma) y metodos para su uso.
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
US20130273055A1 (en) 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
CA2827170A1 (en) 2011-02-11 2012-08-16 David M. Hilbert Monovalent and multivalent multispecific complexes and uses thereof
SG194510A1 (en) 2011-04-22 2013-12-30 Emergent Product Dev Seattle Prostate-specific membrane antigen binding proteins and related compositionsand methods
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EP2714738B1 (de) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und ihre verwendungen
CN102898527B (zh) * 2011-07-25 2016-12-21 三星电子株式会社 融合蛋白、药物组合物及预防或治疗癌症的方法
JP6216317B2 (ja) * 2011-09-09 2017-10-18 メディミューン リミテッド 抗Ｓｉｇｌｅｃ−１５抗体およびその使用
CA2850291A1 (en) * 2011-09-29 2013-04-04 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US10946104B2 (en) 2012-01-13 2021-03-16 Apo-Tb.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
HK1212237A1 (en) 2012-08-31 2016-06-10 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
EP4088737A3 (de) 2012-09-05 2023-02-08 University Of Virginia Patent Foundation Target-peptide für therapie und diagnostik von kolorektalkarzinomen
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US20160000893A1 (en) 2012-12-13 2016-01-07 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JP6501270B2 (ja) 2013-03-14 2019-04-17 ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ 標的化剤抗体抱合体およびその使用
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
JP6693872B2 (ja) 2013-07-25 2020-05-13 シトムクス セラピューティクス，インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
CN105829349B (zh) 2013-10-15 2023-02-03 斯克利普斯研究所 肽嵌合抗原受体t细胞开关和其用途
CN106459990B (zh) 2014-02-07 2021-06-01 麦克马斯特大学 三功能t细胞抗原偶联物及其制备方法和用途
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EP3137100B1 (de) 2014-04-15 2023-12-20 University Of Virginia Patent Foundation Isolierte t-zellenrezeptoren und verfahren zur verwendung davon
KR20170010863A (ko) 2014-07-01 2017-02-01 화이자 인코포레이티드 이중특이성 이종이량체성 디아바디 및 이의 용도
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
EP3201227A4 (de) 2014-09-29 2018-04-18 Duke University Bispezifische moleküle mit einem hiv-1-hüll-targeting-arm
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
AU2016232693B2 (en) 2015-03-19 2021-08-12 Duke University HIV-1 neutralizing antibodies and uses thereof
WO2016149698A2 (en) 2015-03-19 2016-09-22 Duke University Hiv-1 neutralizing antibodies and uses thereof (v3 antibodies)
WO2016149710A2 (en) 2015-03-19 2016-09-22 Duke University Hiv-1 neutralizing antibodies and uses thereof
US10450368B2 (en) 2015-03-19 2019-10-22 Duke University HIV-1 neutralizing antibodies and uses thereof (CD4bs antibodies)
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
EP3283113A4 (de) 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimierte pne-basierte chimäre t-zell-rezeptor-schalter und verwendungen davon
MX383614B (es) 2015-05-21 2025-03-14 Harpoon Therapeutics Inc Proteinas de union triespecificas y metodos de uso.
WO2016204966A1 (en) * 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
AU2016306304A1 (en) 2015-08-07 2018-03-22 The University Of Birmingham Identification of class I MHC associated glycopertides as targets for cancer immunotherapy
KR20250008141A (ko) 2015-08-07 2025-01-14 이미지냅 인코포레이티드 분자를 표적화하기 위한 항원 결합 구조체
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
KR102777500B1 (ko) 2015-09-23 2025-03-11 리제너론 파아마슈티컬스, 인크. 최적화된 항-cd3 이중특이적 항체 및 이의 용도
CN116059316A (zh) 2015-10-23 2023-05-05 优瑞科生物技术公司 抗体/t细胞受体嵌合构建体及其用途
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
GB201520191D0 (en) 2015-11-16 2015-12-30 Cancer Rec Tech Ltd T-cell receptor and uses thereof
CN109069635B (zh) 2016-02-04 2023-09-26 斯克利普斯研究所 人源化抗cd3抗体、偶联物及其用途
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
AU2017267793B2 (en) 2016-05-20 2024-01-25 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US10738130B2 (en) 2016-09-23 2020-08-11 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof
MA46417A (fr) 2016-09-23 2019-07-31 Regeneron Pharma Anticorps anti-steap2, conjugués anticorps-médicament, et molécules bispécifiques de liaison à l'antigène qui se lient à steap2 et cd3, et leurs utilisations
KR102613430B1 (ko) 2016-10-19 2023-12-18 더 스크립스 리서치 인스티튜트 인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도
KR102275008B1 (ko) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
US10844134B2 (en) 2016-11-23 2020-11-24 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
DK3579848T3 (da) 2017-02-08 2025-01-20 Dragonfly Therapeutics Inc Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
KR20240060739A (ko) 2017-02-20 2024-05-08 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
AU2018258045B2 (en) 2017-04-26 2024-02-29 Eureka Therapeutics, Inc. Chimeric antibody/T-cell receptor constructs and uses thereof
AU2018266711B2 (en) * 2017-05-08 2025-02-06 Adimab, Llc Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
CA3067772A1 (en) 2017-06-30 2019-01-03 Marieke GRIFFIOEN Treatment of haematological malignancies
US11390686B2 (en) 2017-08-09 2022-07-19 University Of Saskatchewan HER3 binding agents and uses thereof
JP7227630B2 (ja) 2017-10-12 2023-02-22 マックマスター ユニバーシティー Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
SI3694529T1 (sl) 2017-10-13 2024-10-30 Harpoon Therapeutics, Inc. Trispecifične beljakovine in načini uporabe
SG11202007579TA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
AR115360A1 (es) 2018-02-08 2021-01-13 Genentech Inc Moléculas de unión al antígeno y métodos de uso
JP7353576B2 (ja) 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
BR112020023330A2 (pt) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
MA52777A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Agents de liaison psma et utilisations correspondantes
WO2019231326A1 (en) 2018-05-31 2019-12-05 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n.LUMC) Teipp neoantigens and uses thereof
MY208638A (en) 2018-07-02 2025-05-21 Amgen Inc Anti-steap1 antigen-binding protein
US10640562B2 (en) 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EP3833385A4 (de) 2018-08-08 2021-12-22 Dragonfly Therapeutics, Inc. Proteine, die nkg2d, cd16 und ein tumor-assoziiertes antigen binden
EP3833392A4 (de) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. Multispezifische bindende proteine zur bindung von cd33, nkg2d und cd16 sowie verfahren zur verwendung
PT3844189T (pt) 2018-08-31 2025-01-29 Regeneron Pharma Estratégia de dosagem que mitiga a síndrome de libertação de citocinas para anticorpos bisepecíficos contra cd3/c20
WO2020052542A1 (en) 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cll1 and constructs thereof
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (de) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3-bindende proteine und verfahren zur verwendung
NL2021789B1 (en) 2018-10-10 2020-05-14 Academisch Ziekenhuis Leiden Binding proteins specific for HA-1H and uses thereof
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
AR118720A1 (es) 2019-04-19 2021-10-27 Janssen Biotech Inc Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
KR20220008866A (ko) 2019-05-14 2022-01-21 하푼 테라퓨틱스, 인크. EpCAM 결합 단백질 및 사용 방법
WO2020247929A1 (en) 2019-06-07 2020-12-10 Adimab, Llc High affinity anti-cd3 antibodies, and methods for their generation and use
BR112022011357A2 (pt) 2019-12-13 2022-08-23 Genentech Inc Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo
WO2021146328A1 (en) 2020-01-13 2021-07-22 Aptevo Research And Development Llc Formulations for protein therapeutics
KR20220140500A (ko) 2020-01-13 2022-10-18 압테보 리서치 앤드 디벨롭먼트 엘엘씨 약물 전달 시스템 성분에 대한 치료제 단백질의 흡착을 방지하기 위한 방법 및 조성물
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
IL297412A (en) 2020-05-04 2022-12-01 Immunorizon Ltd Precursor tri-specific antibody constructs and methods of use thereof
CN115836088A (zh) 2020-05-06 2023-03-21 蜻蜓疗法股份有限公司 结合nkg2d、cd16和clec12a的蛋白质
NL2026614B1 (en) 2020-10-02 2022-06-03 Academisch Ziekenhuis Leiden T cell receptors directed against bob1 and uses thereof
EP4259193A4 (de) 2020-12-09 2025-01-15 Janux Therapeutics, Inc. Zusammensetzungen und verfahren im zusammenhang mit tumoraktivierten antikörpern gegen psma und effektorzellantigene
KR20230137393A (ko) 2021-01-28 2023-10-04 얀센 바이오테크 인코포레이티드 Psma 결합 단백질 및 이의 용도
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
US12258406B2 (en) 2021-03-24 2025-03-25 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
KR20240007171A (ko) 2021-05-14 2024-01-16 제넨테크, 인크. 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
JP2024519964A (ja) 2021-05-21 2024-05-21 アプティーボ リサーチ アンド デベロップメント エルエルシー タンパク質治療薬のための投薬レジメン
EP4347660A4 (de) 2021-06-01 2025-06-04 Triumvira Immunologics USA, Inc. Claudin-18.2-t-zell-antigen-koppler und verwendungen davon
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
JP2024540461A (ja) * 2021-11-19 2024-10-31 武▲漢▼友芝友生物制▲薬▼股▲ふん▼有限公司 二重特異性抗体及びその用途
NL2030990B1 (en) 2022-02-17 2023-09-01 Academisch Ziekenhuis Leiden T cell receptors directed against jchain and uses thereof
NL2031118B1 (en) 2022-03-01 2023-09-07 Academisch Ziekenhuis Leiden T cell receptors directed against transcription factor wt1 and uses thereof
EP4493592A1 (de) 2022-03-14 2025-01-22 LamKap Bio gamma AG Bispezifische gpc3xcd28- und gpc3xcd3-antikörper und deren kombination zur gezielten tötung gpc3-positiver maligner zellen
US20250304651A1 (en) 2022-05-13 2025-10-02 Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) Treatment of haematological malignancies
NL2032130B1 (en) 2022-06-10 2023-12-18 Academisch Ziekenhuis Leiden T cell receptors directed against melanoma-associated antigen and uses thereof
NL2033510B1 (en) 2022-11-11 2024-05-28 Academisch Ziekenhuis Leiden T cell receptors directed against cancer-associated antigens and uses thereof
CN120917051A (zh) 2023-03-16 2025-11-07 天劢源和有限公司(开曼) 多特异性抗原结合蛋白及其用途
NL2034658B1 (en) 2023-04-21 2024-10-28 Academisch Ziekenhuis Leiden TIMP3-derived TEIPP neoantigens and uses thereof
NL2034657B1 (en) 2023-04-21 2024-10-28 Academisch Ziekenhuis Leiden RCN1-derived TEIPP neoantigens and uses thereof
NL2036854B1 (en) 2024-01-22 2025-08-01 Academisch Ziekenhuis Leiden Haematopoietic-restricted Minor Histocompatibility Antigens and uses thereof
NL2036853B1 (en) 2024-01-22 2025-08-01 Academisch Ziekenhuis Leiden Haematopoietic-restricted minor histocompatibility antigens and uses thereof
WO2025188909A1 (en) 2024-03-06 2025-09-12 Mdx Management Llc Shp-1 inhibitor conjugates with pro-inflammatory compounds
WO2025245399A1 (en) 2024-05-23 2025-11-27 Indapta Therapeutics, Inc. Method of treating cancer with natural killer cells
NL2037811B1 (en) 2024-05-29 2025-12-12 Univ Oslo Treatment for Cancer
WO2026086936A1 (en) 2024-10-24 2026-04-30 Itabmed Co., Ltd. Uses of multispecific antigen binding proteins capable of binding cd19 and cd3

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1696031E (pt) * 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
WO2001071005A2 (en) * 2000-03-24 2001-09-27 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex

Also Published As

Publication number Publication date
AU2004242845B2 (en) 2011-06-02
EP1629011A2 (de) 2006-03-01
US8784821B1 (en) 2014-07-22
WO2004106380A2 (en) 2004-12-09
AU2004242845A1 (en) 2004-12-09
CA2523716C (en) 2014-11-25
CA2523716A1 (en) 2004-12-09
SI1629011T1 (sl) 2010-05-31
EP1629011B1 (de) 2010-01-13
DE602004025101D1 (de) 2010-03-04
WO2004106380A3 (en) 2005-06-23
DK1629011T3 (da) 2010-05-03

Similar Documents

Publication Publication Date Title
DK1629011T3 (da) Humane anti-humane-DC3-bindingsmolekyler
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
WO2005103081A3 (en) Human monoclonal antibodies against cd20
CY1121254T1 (el) Συνθεσεις αντισωματων anti-ctla-4
PT1766093E (pt) Anticorpos contra toxinas de clostridium difficile e utilizações dos mesmos
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
DE602006013029D1 (de) Anti-egfr-antikörper
GEP20105110B (en) Rage fusion proteins and their use
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
EA201100923A1 (ru) Антитела человека против тканевого фактора
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
EA200700917A1 (ru) Способ рефолдинга рекомбинантных антител
CY1114658T1 (el) Πρωτεϊνες δεσμευσης αντιγονου του αυξητικου παραγοντα τυπου επιδερμικου αυξητικου παραγοντα προσδεσης στην ηπαρινη
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
NL1026829A1 (nl) Gemodificeerde humane IGF-1R-antilichamen.
MX2010006767A (es) Anticuerpos de virus de hepatitis c.
TW200510459A (en) RG1 antibodies and uses thereof
ATE414535T1 (de) Trägerproteine für impfstoffe
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
ATE517920T1 (de) Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
DE602005027399D1 (de) Für humane matriptase spezifische bindungsproteine
WO2004069860A3 (en) Isg15-conjugated proteins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties